Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

DOCK11 deficiency in patients with X-linked actinopathy and autoimmunity

Charlotte Boussard, Laure Delage, Tania Gajardo, Alexandre Kauskot, Maxime Batignes, Nicolas Goudin, Marie-Claude Stolzenberg, Camille Brunaud, Patricia Panikulam, Quentin Riller, Maryse Moya-Nilges, Jean Solarz, Christelle Repérant, Béatrice Durel, Jean-Claude Bordet, Olivier Pellé, Corinne Lebreton, Aude Magérus, Vithura Pirabakaran, Pablo Vargas, Sébastien Dupichaud, Marie Jeanpierre, Angélique Vinit, Mohammed Zarhrate, Cécile Masson, Nathalie Aladjidi, Peter D. Arkwright, Brigitte Bader-Meunier, Sandrine Baron Joly, Joy Benadiba, Elise Bernard, Dominique Berrebi, Christine Bodemer, Martin Castelle, Fabienne Charbit-Henrion, Marwa Chbihi, Agathe Debray, Philippe Drabent, Sylvie Fraitag, Miguel Hié, Judith Landman-Parker, Ludovic Lhermitte, Despina Moshous, Pierre Rohrlich, Frank Ruemmele, Anne Welfringer-Morin, Maud Tusseau, Alexandre Belot, Nadine Cerf-Bensussan, Marie Roelens, Capucine Picard, Bénédicte Neven, Alain Fischer, Isabelle Callebaut, Mickaël Ménager, Fernando E. Sepulveda, Frédéric Adam, Frédéric Rieux-Laucat

Blood (2023) 141 (22): 2713–2726.

https://doi.org/10.1182/blood.2022018486

Published: 2023

Includes: Supplemental data

Journal Articles

HIF2α is a direct regulator of neutrophil motility

Sundary Sormendi, Mathieu Deygas, Anupam Sinha, Mathilde Bernard, Anja Krüger, Ioannis Kourtzelis, Gregoire Le Lay, Pablo J. Sáez, Michael Gerlach, Kristin Franke, Ana Meneses, Martin Kräter, Alessandra Palladini, Jochen Guck, Ünal Coskun, Triantafyllos Chavakis, Pablo Vargas, Ben Wielockx

Blood (2021) 137 (24): 3416–3427.

https://doi.org/10.1182/blood.2020007505

Published: 2021

Includes: Supplemental data

Journal Articles

Imatinib (IMA) Low Dose Reduction Program (LDR) in Chronic Myeloid Leukemia Ph+ (CML Ph+) in a Single Reference Institution in Mexico City. Ongoing Preliminary Results

Rafael Hurtado Monroy, MD, Pablo Vargas-Viveros, MD, Carrillo Munoz Silvia, RN

Blood (2019) 134 (Supplement_1): 5921.

https://doi.org/10.1182/blood-2019-130873

Published: 2019

Journal Articles

Hyperimmunoglobulin E Syndrome (HIES) Treated with Thalidomide Plus Dexamethasone with Encouraging Results

Rafael Hurtado Monroy, MD, Pamela Denisse Soberanis Pina, MD, Juan Jose Calva Mercado, Jose Pablo Vargas Viveros, Catalina Romo Aguirre

Blood (2017) 130 (Supplement 1): 4822.

https://doi.org/10.1182/blood.V130.Suppl_1.4822.4822

Published: 2017

Journal Articles

Significant Improvement In Quality Of Life (QoL) In Patients With Chronic Myeloproliferative Neoplasms and Myelofibrosis Treated With JAK-1 and JAK-2 Inhibitor Ruxolitinib. A Single Institution Experience In Mexico

Pablo Vargas-Viveros, MD, Rafael Hurtado Monroy, MD, Myrna Candelaria-Hernandez, MD

Blood (2013) 122 (21): 5252.

https://doi.org/10.1182/blood.V122.21.5252.5252

Published: 2013

Journal Articles

Imatinib (IM) Plus Thalidomide (Thali), A Effective Combination For The Treatment Of Chronic Myeloid Leukemia (CML) Philadelphia ChromosomePositive (Ph +) In IM-Resistant Disease. Report Of 14 New Cases From A Single Center In Mexico

Rafael Hurtado Monroy, MD, Pablo Vargas-Viveros, MD, Eduardo Cervera Ceballos, MD, Judith Cruz Velazquez, Silvia Carrillo Munos, RN

Blood (2013) 122 (21): 5172.

https://doi.org/10.1182/blood.V122.21.5172.5172

Published: 2013

Journal Articles

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Giovanni Barosi, MD, Mohan Agarwal, MD, MNAMS, Sonja Zweegman, MD, PhD, Wolfgang Willenbacher, MD, Sima Pakstyte, MD, Reinier Raymakers, MD, PhD, Nathan Cantoni, MD, Ankur Modi, Mahmudul Khan, PhD, Jose Ricardo Perez, MD, Hans Hasselbalch, MD, Jose Pablo Vargas Viveros, MD, Camila C.G. Linardi, MD, PhD, Heinz Gisslinger, MD, Adelmo Henrique Daumas Gabriel, MD, Francesca Palandri, David Lavie, MD, Claire N Harrison, DM FRCP FRCPath

Blood (2012) 120 (21): 2844.

https://doi.org/10.1182/blood.V120.21.2844.2844

Published: 2012

Journal Articles

Chronic Myeloid Leukemia Philadelphia Chromosome Positive (CML Ph+) with Imatinib (IM) Intolerance or Resistant Disease. Response to Thalidomide (TALI) Treatment. Preliminary Report of a Serial of Cases with Encouraging Results

Rafael Hurtado, MD, Jose Pablo Vargas Viveros, MD, Carrillo Muñoz Silvia, RN, Judith Cruz-Velazquez, Myrna Candelaria, MD, PhD, Eduardo Cervera, MD

Blood (2012) 120 (21): 1689.

https://doi.org/10.1182/blood.V120.21.1689.1689

Published: 2012

Journal Articles

Compassionate Use Program (CUP) with Ruxolitinib in Mexican Patients with Primary Myelofibrosis (PMF), Post – Polycythemia, Vera Myelofibrosis (PPV – MF), and Post–Essential Thrombocythemia Myelofibrosis (PET – MF)

Pablo Vargas, MD, Roberto Ovilla, MD, Martha Alvarado, MD, Manuel Lopez, MD, Rafael Hurtado Monroy, MD., Juan_Carlos Solis, MD, Alejandro Limon, MD, Gladys Agreda, MD, Salvador Silva, MD, Juan Julio Kassack, MD, Saida Zavala, MD, Carlos Aguilar, MD, Enrique Baez, Esperanza Barrera, MD, Antonio Osuna, MD, Javier Morales, MD, Aquileo Herrera, MD

Blood (2012) 120 (21): 5067.

https://doi.org/10.1182/blood.V120.21.5067.5067

Published: 2012

Journal Articles

Hemolytic Intravascular Anemia (HIA) Microangiopathic-Like and Deep Venous Thrombosis (DVT) Due to Ozone Exposure: Case Report

Luis Fernando Cortázar-Benítez, Pablo Vargas Viveros, MD, Alfredo Aiza Alvarez, Rafael Hurtado Monroy, MD.

Blood (2011) 118 (21): 5278.

https://doi.org/10.1182/blood.V118.21.5278.5278

Published: 2011

Journal Articles

Hyper Immunoglobulin E Syndrome (HIES): Report of a New Case Treated with Omalizumab and Dexametasone

Luis Fernando Cortázar-Benítez, R.M. Rojas Sotelo, Pablo Vargas-Viveros, MD, Rafael Hurtado-Monroy, MD., Catalina Romo Aguirre, MD, Jorge Valenzuela Tamariz, MD, Alejandra Zárate, MD, Sergio Masse, MD

Blood (2011) 118 (21): 4934.

https://doi.org/10.1182/blood.V118.21.4934.4934

Published: 2011

Journal Articles

The Age of Mexican Patients with Chronic Myeloid Leukemia (CML) Ph+ Is Quite Younger Than the Reported in USA and European Series.

Pablo Vargas-Viveros, M.D., Rafael Hurtado Monroy, MD, Eduardo Cervera, MD, Carlos Best, M.D., Alvaro Aguayo, M.D., Myrna Candelaria, MD

Blood (2009) 114 (22): 4291.

https://doi.org/10.1182/blood.V114.22.4291.4291

Published: 2009

Journal Articles

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Blood (2008) 112 (11): 4275.

https://doi.org/10.1182/blood.V112.11.4275.4275

Published: 2008

Journal Articles

Compassionate Use of Nilotinib (AMN107) in Mexican Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib.

Manuel Ayala, MD, Rafael Hurtado, MD, Kevin Nacho, MD, Norma Tapia, MD, Martha Alvarado, MD, Alvaro Aguayo, MD, Sergio Cleto, MD, Yolanda Lugo, MD, Gustavo Reyes, MD, Pablo Vargas, MD, Angel Herrera, Luis Antonio Meillon, MD

Blood (2007) 110 (11): 4578.

https://doi.org/10.1182/blood.V110.11.4578.4578

Published: 2007

Journal Articles

Imatinib Alone (IA) Vs. Imatinib + Ara-C (IMAC): A Randomized Phase III Clinical Trial for the Treatment of Early Phase (EP) Chronic Myeloid Leukemia (CML) Ph+. Preliminary Report of Mexican Cooperative Leukemia Group (GRUMELA).

Rafael Hurtado Monroy, MD, Pablo Vargas-Viveros, MD, Eduardo Cervera, MD, Myrna Candelaria, MD, Alvaro Aguayo, MD, Emma Gallardo, MD, Eucario Leon, MD, Juan Labardini, MD, Ricardo Sosa, MD, Rogelio Paredes, MD, Fernando Romero, MD, Oscar Perez, MD, Omar Coronel-Ayala, MD

Blood (2004) 104 (11): 1015.

https://doi.org/10.1182/blood.V104.11.1015.1015

Published: 2004

NARROW

DOCK11 deficiency in patients with X-linked actinopathy and autoimmunity

HIF2α is a direct regulator of neutrophil motility

Imatinib (IMA) Low Dose Reduction Program (LDR) in Chronic Myeloid Leukemia Ph+ (CML Ph+) in a Single Reference Institution in Mexico City. Ongoing Preliminary Results

Hyperimmunoglobulin E Syndrome (HIES) Treated with Thalidomide Plus Dexamethasone with Encouraging Results

Significant Improvement In Quality Of Life (QoL) In Patients With Chronic Myeloproliferative Neoplasms and Myelofibrosis Treated With JAK-1 and JAK-2 Inhibitor Ruxolitinib. A Single Institution Experience In Mexico

Imatinib (IM) Plus Thalidomide (Thali), A Effective Combination For The Treatment Of Chronic Myeloid Leukemia (CML) Philadelphia ChromosomePositive (Ph +) In IM-Resistant Disease. Report Of 14 New Cases From A Single Center In Mexico

An Individual Patient Supply Program for Ruxolitinib for the Treatment of Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).

Chronic Myeloid Leukemia Philadelphia Chromosome Positive (CML Ph+) with Imatinib (IM) Intolerance or Resistant Disease. Response to Thalidomide (TALI) Treatment. Preliminary Report of a Serial of Cases with Encouraging Results

Compassionate Use Program (CUP) with Ruxolitinib in Mexican Patients with Primary Myelofibrosis (PMF), Post – Polycythemia, Vera Myelofibrosis (PPV – MF), and Post–Essential Thrombocythemia Myelofibrosis (PET – MF)

Hemolytic Intravascular Anemia (HIA) Microangiopathic-Like and Deep Venous Thrombosis (DVT) Due to Ozone Exposure: Case Report

Hyper Immunoglobulin E Syndrome (HIES): Report of a New Case Treated with Omalizumab and Dexametasone

The Age of Mexican Patients with Chronic Myeloid Leukemia (CML) Ph+ Is Quite Younger Than the Reported in USA and European Series.

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Compassionate Use of Nilotinib (AMN107) in Mexican Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib.

Imatinib Alone (IA) Vs. Imatinib + Ara-C (IMAC): A Randomized Phase III Clinical Trial for the Treatment of Early Phase (EP) Chronic Myeloid Leukemia (CML) Ph+. Preliminary Report of Mexican Cooperative Leukemia Group (GRUMELA).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only